Objectives To investigate the effect of chronic antioxidant treatments on the development of nitrate tolerance in spontaneously hypertensive (SHR) and normotensive Wistar±Kyoto (WKY) rats by evaluating (i) coronary vascular reactivity, (ii) lipid peroxidation (malondialdehyde), and (iii) peroxynitrite formation (3-nitrotyrosine).
Methods Tolerance was induced in 16-week-old male SHR and WKY, by 4 days of continuous treatment with nitroglycerin patches. Two groups were orally pre-treated (2-weeks) with antioxidants: N-acetyl-L-cysteine (NAC) or melatonin. Effects of serotonin (5-HT) and sodium nitroprusside (SNP) perfusion were tested in isolated Langendorff-perfused hearts. 3-nitrotyrosine levels were measured in coronary sinus ef¯uent and malondialdehyde in plasma.
Results Nitrate tolerance reduced SNP-induced dilation in both strains. This alteration was differently improved by antioxidants: melatonin was effective in SHR, whereas NAC was effective in WKY. Tolerance also reduced 5-HTmediated vasodilation in WKY, which was reversed by both antioxidants. By contrast, nitrate tolerance enhanced the vasoconstriction to 5-HT in SHR and both antioxidants prevented this response. Furthermore, tolerance was associated with higher malondialdehyde levels in both strains and with higher 3-nitrotyrosine levels in SHR. These changes were reversed by both antioxidants.
Conclusions A participation of oxidative stress was suggested during nitrate tolerance development, since antioxidants prevented the increase in lipid peroxidation and improved vascular responses to SNP and 5HT. Differential effects of antioxidants on SNP-induced vasodilation in SHR and WKY may suggest distinct mechanisms of tolerance development in hearts from hypertensive and normotensive rats. An increased peroxynitrite generation, expressed by higher 3-nitrotyrosine levels, could contribute to nitrate tolerance in the coronary circulation of SHR. 
Introduction
Arterial hypertension represents a risk factor for the development of coronary artery disease as well as an aggravating factor, once symptomatic ischaemic heart disease develops. Coronary¯ow reserve may be negatively affected by hypertension, through the development of left ventricular hypertrophy, the acceleration of epicardial coronary atherosclerosis, and coronary microvascular alteration [1] , thereby making the myocardium more vulnerable to ischaemia. Nitrate vasodilators are often used in association with beta-blocking drugs and calcium-channel antagonists in the management of ischaemic and hypertensive patients, but little is known about development of nitrate tolerance under those conditions. The major limitation of nitrate use in clinical practice to treat ischaemic normotensive patients is that the rapid development of tolerance towards their anti-ischaemic and haemodynamic effects has been widely described following chronic administration of nitrates [2] . Moreover, in in vivo studies, a cross-tolerance against inorganic nitrovasodilators and endothelium-dependent vasodilators was demonstrated in association with nitrate tolerance [3] . Although the exact mechanism of tolerance remains unknown, several mechanisms have been proposed [4] . Recent experimental observations have shown an increased generation of the vascular superoxide anion (´O 2 À ) in nitrate tolerance, which could enhance nitric oxide (NO) degradation [4, 5] . The interaction between´O 2 À and NO, endothelium-derived or exogenously administered such as during nitrate therapy, produces, in vivo, peroxynitrite anion (ONOO À ) [6] . ONOO À , which is a highly reactive moiety, can also alter vascular reactivity and favour vascular injury by inducing peroxidation of lipids [7] and tyrosine nitration of proteins [8] as well as by depleting cellular glutathione stores [9] . Moreover, an over-production of´O 2 À and a concomitant decrease of antioxidant levels have also been reported to occur in human essential hypertension [10] and in spontaneously hypertensive rats (SHR) [11, 12] . These factors could facilitate tolerance development when ischaemic conditions are associated with hypertension during prolonged nitrovasodilator treatment.
The aim of the present study was to evaluate in SHR and in their normotensive Wistar±Kyoto controls (WKY) the effects of two chronic antioxidant treatments, N-acetyl-L-cysteine (NAC) or melatonin, on nitrovasodilator tolerance development in the coronary resistance vascular bed. This was achieved by measuring the coronary microcirculation reactivity to sodium nitroprusside (SNP), an exogenous and inorganic NO donor, to serotonin (5-HT), an endothelium-dependent NO-releasing drug, and to papaverine (PAP), an inhibitor of phosphodiesterase that increases cAMP and relaxes vascular smooth muscle. Sixteen-week-old SHRs were used because, at this age, hypertension is well-established and cardiac hypertrophy with reduced coronary reserve¯ow has developed. NAC, a thiol donor, which increases the glutathione stores, and melatonin, the pineal neurohormone and an endogenous antioxidant, were chosen for their recognized ef®cacy to scavenge different species of oxygen free radicals [13] including ONOO À [14, 15] . In addition, the effects of antioxidant treatments on plasma levels of malondialdehyde, a known index of lipid peroxidation, and of free 3-nitro-L-tyrosine formation in coronary vascular beds, an index of ONOO À production [8] , were measured in these studies.
Methods
Animals, treatments, and in vivo nitrate tolerance All animals were housed and treated in accordance with Canadian Council on Animal Care guidelines and the protocols were approved by the Local Institutional Animal Ethics Committee. Male SHR and WKY were obtained from Charles River Laboratories (Charles River, St Constant, Quebec, Canada). Animals were housed under a 12 h light±dark cycle, at constant humidity and temperature, with free access to standard laboratory rat chow (Basal Puri®ed Diet 5755C, Purina Mills Inc., St Louis, Missouri, USA) and drinking water. Nitrate tolerance was induced in 16-week-old rats by the continuous application of nitroglycerin patches (the size of nitroglycerin patch was adjusted to the body weight to release a dose in vivo of 1.5 ìg/h per g body mass) to the shaved dorsal skin between the scapulae over a period of 4 days. Two groups from each strain were orally pre-treated for 2 weeks with antioxidants: either NAC (4 g/kg per day) or melatonin (30 mg/kg per day). A high dose of NAC was used in the present study because of its poor oral biovailability (4±10%) [13] . NAC and melatonin at these concentrations, in previous experiments, induced similar reductions in plasma lipid peroxidation (plasma malondialdehyde) in Sprague±Dawley normotensive rats exposed to oxidative stress. NAC was dissolved in drinking water whereas melatonin was dissolved in absolute ethanol and then added to the drinking water (the ®nal ethanol concentration was 0.3%). NAC and melatonin solutions were freshly prepared daily and administered in dark bottles in the evening (between 2000 and 2200 h) to respect the physiological circadian rhythm of pineal hormone. No differences in daily water intake were observed between NAC-treated and melatonin-treated groups. Indirect tail-cuff measurements of systolic blood pressure (BP) were made in conscious rats by plethysmography (Harvard Apparatus Ltd, South Natick, Massachusetts, USA) during antioxidant treatments and nitrate tolerance development and recorded on a Maclab/8 system (AD Instruments Ltd, Castle Hill, New South Wales, Australia): four to ®ve measurements were taken in each rat and then averaged. The experimental groups comprise both nitrate-tolerant and non-tolerant rats from both strains.
Experiments on non-tolerant animals
Experiments were performed on six groups of rats: control groups (SHR n 7, WKY n 7), NAC-treated groups (SHR-NAC n 9, WKY-NAC n 7) and melatonin-treated groups (melatonin-treated-SHR n 8, melatonin-treated-WKY n 7).
Experiments on nitrate-tolerant animals
Eight groups of rats were used: control groups (SHR n 7, WKY n 7), nitrate-tolerant groups: tolerant SHR (n 4), tolerant WKY (n 4), tolerant NACtreated SHR (n 4), tolerant NAC-treated WKY (n 4), tolerant melatonin-treated SHR (n 4), and tolerant melatonin-treated WKY (n 4).
Heart preparation
At the end of the fourth day of nitroglycerin patch application, rats from each group were anaesthetized with CO 2 and rapidly decapitated. The chest was quickly opened and the heart excised and immersed in ice-cold heparinized buffer (10 IU/ml). The heart was immediately mounted on the experimental set-up and perfused (Langendorff model) at constant¯ow by means of a digital roller pump. A 20 ml compliance chamber along the perfusion line ensured a continuous ow. The¯ow rate was adjusted during the stabilization period to obtain a coronary perfusion pressure of 75 mmHg and was held constant throughout the study. The¯ow rate was measured throughout the experiment with an in-line ultrasonic¯ow probe and meter (Transonic System Inc., model T106) and maintained constant during the whole experiment. The heart was perfused with a modi®ed Krebs±Henseleit±tyrosine buffer (K-H-tyr) containing (in mmol/l): NaCl 118, KCl 4, CaCl 2 2.5, KH 2 PO 4 1.2, MgSO 4 1, NaHCO 3 24, Dglucose 5, sodium pyruvate 2, and L-tyrosine 0.3. To avoid precipitation, L-tyrosine was dissolved in 1.5 ml of NaOH (0.1 mol/l) and added to 6 l of K-H-tyr buffer. The pH was maintained rigorously at 7.40. The solution was continuously gassed with 95% O 2 ±5% CO 2 and warmed at 378C. L-tyrosine was added to the Krebs±Henseleit buffer in order to induce its nitration by the ONOO À released from the coronary vascular bed to form 3-nitrotyrosine measured in the coronary ef¯uent from the heart. No detectable amount of 3-nitrotyrosine was measured when hearts were perfused with a Krebs±Henseleit buffer without L-tyrosine. The addition of L-tyrosine to the buffer did not cause alteration in coronary vascular reactivity, since similar results were observed using L-tyrosine-free Krebs± Henseleit buffer in the organ chamber. Coronary perfusion pressure was measured with a pressure transducer connected to a sidearm of the aortic perfusion cannula. All drugs were administered through a Y connector in the aortic cannula with a syringe pump (Harvard Apparatus Ltd, model 11) at 1±3% of the coronary¯ow rate. Adequate mixing of the drugs was ensured by the turbulent¯ow created in the reverse drop-shaped aortic cannula. All quoted concentrations refer to the ®nal concentration after mixing. Data were recorded on a polygraph system (AG-620, Nihon-Kohden America Inc., Irvine, California, USA).
Experimental protocol
In this study, nitroglycerin was not used to test nitrate tolerance development in coronary microcirculation because organic nitrates such as nitroglycerin did not relax this vascular bed or did so only to a lesser degree and at very high doses because the enzymes responsible for release of NO from organic nitrates are not expressed in resistance coronary vessels [16] . Consequently, we measured coronary vascular responses to an inorganic, endothelium-independent nitrovasodilator, SNP, (3 3 10 À7 to 10 À4 mol/l) and to 5-HT (10 À7 to 3 3 10 À5 mol/l), an endothelium-derived NO releasing drug, by creating a concentration±response curve after an equilibration period of 20 min. The effect of PAP, an inhibitor of phosphodiesterase of cAMP, was also tested at a concentration (3 3 10 À5 mol/l) which induced near-maximal vasodilation.
3-Nitrotyrosine: extraction and measurement
Coronary ef¯uent (4 ml) was collected before and during determination of dose±responses curves to drugs. 3-nitrotyrosine was extracted and concentrated 40-fold to be in the detection range of this substance, which is above 0.15 ìmol/l using high-performance liquid chromatography (HPLC) coupled to an ultraviolet detection system. Brie¯y, columns for solid-phase extraction were used; samples were injected, after adjusting the pH of the solution to 5.65 (isoelectric point of the L-tyrosine), through a conditioned C 18 cartridge (Bond Elut LRC 1211-3027, Varian, Palo Alto, California, USA), and 3-nitrotyrosine was ®nally eluted with 1 ml of HPLC-grade methanol. After evaporation of the solvent in a speed vacuum, the extract was redissolved in a ®nal volume of 100 ìl (equal volumes of methanol and puri®ed water). Aliquots (30 ìl) were injected into the HPLC system by a SIL-9A autoinjector (Shimadzu Scienti®c Instruments Inc., Columbia, Maryland, USA). The formation of 3-nitrotyrosine from L-tyrosine was analyzed by separation in HPLC (Primesphere C18 5 ìm, 25 cm 3 4.6 mm, Phenomenex Inc., Torrance, California, USA), detected by ultraviolet absorbance at 274 nm (Shimadzu SPD-6AV), and recorded on a Chromatography Data System (Shimadzu C-R6A). The mobile phase consisting of 220 mmol/l KH 2 PO 4 ÀH 3 PO 4 (pH 3.01), 0.86 mmol/l sodium dodecyl sulphate and 10% methanol (v/v), was pumped by an isocratic system at a¯ow rate of 0.8 ml/min. Peaks of p-tyrosine, m-tyrosine, o-tyrosine and 3-nitro-p-tyrosine were identi®ed on the spectrum of the co-elution, and quanti®ed by peak height using external standards.
Plasma lipid peroxidation: assay of malondialdehyde usinḡ uorometry
A modi®cation of the analytical method described by Yagi involving the¯uorimetric detection of malondialdehyde was used [17] . To avoid ampli®cation of peroxidation during storage (À808C) and assay, analysis was performed within 1 week from sampling, and 10 ìl of 3 mmol/l butylated hydroxytoluene and 10 ìl of 2 mmol/l desferoxamine were added to the blood sample (1 ml) collected at the time of sacri®ce. Brie¯y, 2 ml of 4 mol/l H 2 SO 4 and 0.25 ml of 10% (w/v) phosphotungstic acid were added to a tube containing 10 ìl of plasma; this mixture was left at room temperature for 10 min before being centrifuged at 2000 g for 10 min. The supernatant was then discarded and the pellet was resuspended in a solution of 1 ml of 4 mol/l H 2 SO 4 and 0.15 ml of 10% (w/v) phosphotungstic acid followed by a second centrifugation (at 2000 g for 10 min). The pellet was then resuspended in 2 ml of water to which 0.5 ml of a mixture of equal volumes of 0.67% thiobarbituric acid aqueous solution and glacial acetic acid was added. This solution was heated at 958C for 60 min in a water bath. After cooling the tubes on ice, 2.5 ml of n-butanol was added and the mixture was agitated on a vortex for 30 s. Finally, the solution was centrifuged again (2000 g for 10 min at room temperature) and the butanol layer transferred for¯uorometric detection (Fluorimeter Model 650, Perkins-Elmer, Norwalk, Connecticut, USA) at a wavelength of 553 nm with excitation at 515 nm against an appropriate blank. A standard curve of malondialdehyde was prepared from different concentrations of tetraethoxypropane, which yielded equimolar amounts of malondialdehyde. All the assays were done in triplicate. 
Results
Blood pressure, heart weight and body weight
Systolic arterial blood pressure was higher in 16-weekold SHR than in WKY (P , 0.01) and was not affected by tolerance development or by antioxidant treatments in both strains, as indicated in Table 1 . Mean body weight was signi®cantly lower in all SHR groups than in age-matched WKY (P , 0.05); 2 weeks of NAC and melatonin treatment did not alter body weights in either strains (Table 1) . Heart/body weight ratio was signi®cantly increased in all groups of SHR as compared to WKY (P , 0.05), suggesting that cardiac hypertrophy is well established in SHR at this age (Table 1) .
Lipid peroxidation: plasma malondialdehyde and effect of NAC and melatonin
Tolerance development induced a signi®cant rise in plasma malondialdehyde in both strains (tolerant SHR 31 AE 7% versus SHR, P , 0.05; tolerant WKY 12 AE 2% versus WKY, P , 0.05) as shown in Figure 1 . The plasma malondialdehyde level was similar in untreated 16-week-old SHR and WKY. NAC treatment signi®cantly decreased malondialdehyde levels both in tolerant and non-tolerant hypertensive (tolerant NACtreated SHR versus tolerant SHR, P , 0.01; NACtreated SHR versus SHR, P , 0.01) and normotensive rats (tolerant NAC-treated WKY versus tolerant-WKY, P , 0.01; NAC-treated WKY versus WKY, P , 0.01) (Fig. 1) . Melatonin also signi®cantly reduced plasma malondialdehyde in both strains (tolerant melatonintreated SHR versus tolerant SHR, P , 0.05; melatonintreated SHR versus SHR, P , 0.05; tolerant NACtreated WKY versus tolerant WKY, P , 0.05; NACtreated WKY versus WKY, P , 0.05) as depicted in Figure 1 .
3-Nitrotyrosine in coronary ef¯uent: effect of NAC and melatonin
No differences in 3-nitrotyrosine formation were detected among untreated, NAC-treated and melatonintreated WKY and SHR (as shown in Fig. 2 ). Tolerance development in SHR induced a 50% rise in free 3-nitrotyrosine levels in coronary ef¯uent (tolerant SHR versus SHR, P , 0.05) whereas no signi®cant differences were found between tolerant WKY and WKY (Fig. 2) . In tolerant NAC-treated SHR and tolerant melatonin-treated SHR signi®cant decreases (P , 0.05) in free 3-nitrotyrosine formation were measured as compared to tolerant SHR, suggesting a protective role of both antioxidants in reducing ONOO À release and consequently the tyrosine nitration (Fig. 2) . By contrast, melatonin and NAC did not signi®cantly alter 3-nitrotyrosine levels in tolerant WKY. Moreover, no signi®-cant differences in free 3-nitrotyrosine were observed during 5-HT, PAP and SNP perfusions in all groups.
Effects of NAC and melatonin on endothelium-independent reactivity Response to sodium nitroprusside Coronary vascular relaxations to SNP in isolated perfused hearts from all studied groups are represented as dose±response curves in Figure 3 , and the respective parameters are shown in Table 2 . An increased maximal relaxation to SNP, without a change in sensitivity, was observed in control untreated SHR as compared to WKY ( Fig. 3 and Table 2 ). NAC and melatonin treatments did not affect dose±response curves as compared to their respective non-tolerant SHR and WKY. Tolerance development induced a rightward shift of the dose±response curves in both WKY and SHR strains suggesting the presence of cross-tolerance against the inorganic nitrovasodilator SNP. Chronic NAC treatment improved the sensitivity without changes in maximal relaxation in tolerant SHR (Fig. 3 , right panel and Table 2 ). A complete prevention of tolerance development was achieved by NAC in tolerant NAC-treated WKY, improving both the sensitivity and maximal relaxation induced by tolerance (Fig. 3 , left panel and Table 2 ). By contrast, melatonin treatment almost completely reversed the negative effect of tolerance development in tolerant SHR on maximal relaxation and sensitivity (Fig. 3 , right panel and Table 2 ). However, no protective effect was observed with melatonin treatment in tolerant WKY (Fig. 3 and Table 2 ).
Response to papaverine
The degree of coronary relaxation by PAP, which relaxes vascular smooth muscle by inhibiting cAMPphosphodiesterase, did not differ signi®cantly among tolerant, non-tolerant, NAC-treated and melatonin-treated WKY and SHR as represented in Table 2 .
Effects of NAC and melatonin on endothelium-dependent reactivity Response to serotonin
In the hearts of non-tolerant WKY, 5-HT induced a dilation of coronary microcirculation that was unchanged by chronic NAC and melatonin treatments. Bar graph showing free 3-nitrotyrosine levels in coronary ef¯uent from isolated hearts of all studied groups of 16-week-old Wistar±Kyoto rats (WKY, open bars) and age-matched spontaneously hypertensive rats (SHR, solid bars). Ã P , 0.05, ÃÃ P , 0.01.
of 5-HT-induced constriction and restored the vasorelaxant effects of 5-HT (Fig. 4 , left panel and Table 2 ). By contrast, in SHR, 5-HT induced a constriction of the coronary circulation that was reduced by the antioxidant treatments; the vasoconstriction observed in non-tolerant SHR was enhanced by tolerance development but this potentiation was prevented by both antioxidant treatments (Fig. 4 , right panel and Table 2 ).
Discussion
The present study evaluated the effects of nitrate tolerance on coronary resistance circulation under both normotensive and hypertensive conditions. Despite the limitation of extrapolating the present ®ndings obtained in rat to other species, the dose of nitrates used in this study may have clinical relevance to the dose of nitrovasodilator used in unstable angina and in heart failure. To date, the majority of experimental and human studies have evaluated the phenomenon of tolerance in conductance vessels, aortas or large epicardial arteries [3, 18, 19] . In fact, coronary resistance vessels are generally insensitive or less sensitive to nitroglycerin and other organic nitrates than conductance and capacitance vessels. For this reason, in this study, an inorganic nitrovasodilator such as SNP, which directly releases NO, without the enzymatic biotransformation required by nitroglycerin, was used [16] .
An increased maximal coronary vasodilation to SNP was observed in non-tolerant SHR compared with WKY. The increase in expression of the soluble guanylate cyclase, the target enzyme of NO, reported by Papapetropoulos et al. [20] , in vascular smooth muscle cells of SHR as compared to WKY, supports our data in coronary resistance vessels. This ®nding may represent a compensatory response against the increased coronary vascular resistance that is present in 16-week-old SHR. In contrast to our observations, other studies have reported decreased or unchanged relaxation responses to SNP in SHR, but those observations were made in conductance arteries [21, 22] . Moreover, we also demonstrated that chronic in vivo antioxidant treatments either with NAC or melatonin did not alter the relaxation to SNP in the coronary microcirculation of both non-tolerant SHR and WKY. These ®ndings are in line with previous reports showing that other free radical scavengers, such as ascorbic acid and glutathione, did not change endothelium-independent SNP-mediated vasorelaxation [23] .
The present study shows that 4 days of continuous nitroglycerin treatment produced, in coronary resistance vessels of both strains, a cross-tolerance to SNP, as well as to serotonin, an endothelium-dependent NO-releasing drug. The cross-tolerance phenomenon against different nitrovasodilators has been debated for a long time and this phenomenon generally occurs when nitrates are administered in vivo [3, 5] . Previous evidence has suggested that an over-production of superoxide anion and free radicals could be responsible for the reduced biological life of SNP-derived NO during nitrate tolerance development in both strains, but even more in SHR, resulting in a lesser activation of vascular smooth muscle guanylate cyclase and thus in a reduced relaxation [4, 11, 12] . This hypothesis is supported by our data demonstrating for the ®rst time an increased generation of peroxynitrite anion, the product of the reaction between NO and´O 2 À , in the coronary vascular bed of tolerant SHR as re¯ected by the higher level of 3-nitrotyrosine in the coronary ef¯uent. The increased generation of ONOO À , which is a weaker stimulator of guanylate cyclase than NO, could result in a reduced production of cyclic GMP and in an impaired vasodilation of coronary bed of those animals [24] .
Differences in the effects of the antioxidant treatments were observed for SNP-mediated vasodilation between SHR and WKY : NAC was more effective in preventing the impaired vasodilation to SNP in tolerant WKY than in tolerant SHR, and, conversely, melatonin was ef®-cient in preventing the impaired vasodilation only in tolerant SHR. Although NAC has been shown, in some studies, to reverse nitrate tolerance, controversies still remain about its ef®cacy in preventing nitrate tolerance development under different pathological conditions [25, 26] . Results from in vivo experiments in normotensive animals demonstrated that the depletion of vascular thiols, previously thought to be one of the mechanisms responsible for the nitrate tolerance, is not involved, but that an alteration in the cellular thiol turnover could be implicated [27] . Apart from the early studies by Needleman et al. [28] who ®rst proposed the presence of thiol as a necessary mechanism for NO donor-mediated vasodilation, little is known about the enzymatic or alternative pathways for formation of in vivo S-nitrosothiols, which are the likely intermediate metabolites responsible for the guanylate cyclase activation [29] . Whether the biochemical pathways of S- nitrosothiol production in tolerant SHR are less ef®-cient because of reduced availability of a speci®c thiol subcellular pool secondary to rapid oxidation by peroxynitrite remains to be clari®ed. However, since NAC could prevent the rise in free 3-nitrotyrosine levels from coronary ef¯uent in tolerant SHR, this may suggest that reactive oxygen or nitrogen species other than peroxynitrite are probably involved in this phenomenon.
Melatonin, which was recently proven to be a very ef®cient direct endogenous scavenger of different reactive species including hydroxyl radical and peroxynitrite [14, 15] , did not affect SNP-mediated relaxation in non-tolerant SHR and WKY and prevented the development of cross-tolerance to SNP in SHR but not in WKY. The bene®cial effects of melatonin, whose plasma levels were found to be decreased in SHR [30] , could depend on its capacity to increase the activity and the expression of cytoplasmic and mitochondrial superoxide dismutases and glutathione peroxidase, particularly in situations of increased oxidative stress [31] . By contrast, the lack of ef®cacy of melatonin in preventing the impairment of vasodilation to SNP in tolerant WKY may be due to the fact that the antioxidant enzymatic defences are less stimulated by tolerance, or that different reactive species are generated in tolerant WKY.
A cross-tolerance to serotonin, a drug that produces its vasodilator effects in coronary resistance vessels via the endothelium-dependent release of NO, was also observed. The loss of NO-dependent vasodilation resulted in a coronary vasoconstriction in tolerant WKY rather than the vasodilation observed in non-tolerant WKY. A similar mechanism may be responsible for the increased vasoconstriction observed in the coronary circulation of tolerant SHR as compared to non-tolerant SHR. Since the vascular effects of serotonin depend on the presence and integrity of the endothelium, the vasoconstriction to serotonin observed in non-tolerant SHR is consistent with the impaired vasodilatory function of coronary microvascular endothelium in this model of hypertension. Moreover, in this study, we observed a reduction of the 5-HT-induced vasoconstriction in non-tolerant SHR treated with antioxidants, whereas no differences in 5-HT-induced vasodilation were found among treated and untreated non-tolerant WKY. The increased free radical production seems to be responsible for the enhanced vasoconstriction to serotonin observed in both strains after tolerance development, but also in non-tolerant SHR, because protective effects were demonstrated with both antioxidant treatments. Several mechanisms may be postulated for the protection achieved by antioxidants on the endothelium-dependent vascular reactivity: ®rst, the possibility of an increase in the biological activity of NO and in prostacyclin synthesis, which are both negatively affected by free radicals [32] ; second, possibly by reduction of the malondialdehyde level which has been recently reported to improve the endothelium-dependent relaxation in rat tail arteries [33] ; third, through the repletion of antioxidant enzymatic (superoxide dismutases and glutathione peroxidase) and nonenzymatic (thiol stores) cellular systems by treatment with NAC and melatonin [31] .
In contrast to the above ®ndings, the development of cross-tolerance and antioxidant treatments did not alter coronary vessel dilatation to PAP, which relaxes smooth muscle by inhibiting phosphodiesterase and by increasing cAMP. This latter ®nding is concordant with previous studies on conductance arteries which showed that forskolin and other agents acting via adenylyl cyclase are not affected by nitroglycerin tolerance or increased free radical generation [4, 5] .
In the present experiments, an increased generation of ONOO À , expressed by the enhanced free 3-nitrotyrosine concentration, is reported for the ®rst time in the coronary vascular bed of tolerant SHR but not in tolerant WKY. However, no differences in basal free 3-nitrotyrosine levels were found between non-tolerant SHR and WKY. Nevertheless, a difference in ONOO À release between SHR and WKY cannot be excluded, since the protein-bound 3-nitrotyrosine concentration was not assessed in the present study and an increase in protein-bound 3-nitrotyrosine in aortas from aortic banding-induced hypertensive rats was recently demonstrated [34] . Neither treatment with NAC nor melatonin changed the free 3-nitrotyrosine level in nontolerant rats of both strains, but they prevented the rise of free 3-nitrotyrosine in coronary ef¯uent of tolerant SHR. These results obtained after the chronic oral administration of antioxidants are in agreement with recent in vitro studies showing a protection by thiol donors and melatonin against peroxynitrite-induced tissue toxicity [15] and speci®cally the nitration of tyrosine [35] .
An increase in plasma lipid peroxidation as re¯ected by higher malondialdehyde levels may be suspected in both tolerant rat groups. The rise was greater in tolerant SHR (31%) than in tolerant WKY (12%), whereas no differences in malondialdehyde were observed between non-tolerant SHR and WKY. These observations suggest that free radical production is increased after tolerance development since antioxidants reversed the rise of malondialdehyde observed in tolerant rats. A smaller decrease in malondialdehyde levels was also observed in control rats following antioxidant therapies. Previous studies reporting a protective effect of NAC and melatonin against lipid peroxidation induced by exogenous oxidative stressors support our observations [36, 37] . Although a higher oxidative stress was postulated in SHR, SHR showed plasma malondialdehyde levels comparable to their WKY counterparts in our study. Other investigators have reported similar basal levels of malondialdehyde in SHR and WKY tissues [38] , although increased lipid peroxidation in plasma and vascular intima was observed in SHR [39] . Some methodological and biological factors could explain these apparent contradictions in SHR. In fact, no single analytical method can give an accurate account of total lipid peroxidation even when optimizing the measure bȳ uorometric detection used in the present study. Further, a variation in tissue oxidative balance may yield different values for malondialdehyde release from different tissues to plasma in SHR and WKY, but individual differences would be attenuated by a dilution in the plasma volume.
In summary, our results show in the coronary resistance circulation that a cross-tolerance towards exogenous or endogenous NO-dependent vasodilators develops in SHR and WKY after chronic treatment with nitroglycerin. Tolerance is associated with an increased plasma lipid peroxidation both in SHR and WKY and with an increased generation of peroxynitrite in the coronary vascular bed of hypertensive rats. The clinical relevance of these observations is not yet known, but these ®ndings might suggest differences in the development of tolerance in normotensive and hypertensive conditions.
